These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A survey of CMV prevention strategies after liver transplantation. Levitsky J; Singh N; Wagener MM; Stosor V; Abecassis M; Ison MG Am J Transplant; 2008 Jan; 8(1):158-61. PubMed ID: 17973961 [TBL] [Abstract][Full Text] [Related]
10. Two strategies for prevention of cytomegalovirus infections after liver transplantation. Simon P; Sasse M; Laudi S; Petroff D; Bartels M; Kaisers UX; Bercker S World J Gastroenterol; 2016 Mar; 22(12):3412-7. PubMed ID: 27022223 [TBL] [Abstract][Full Text] [Related]
11. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Sun HY; Wagener MM; Singh N Am J Transplant; 2008 Oct; 8(10):2111-8. PubMed ID: 18828771 [TBL] [Abstract][Full Text] [Related]
12. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A; Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174 [TBL] [Abstract][Full Text] [Related]
14. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744 [TBL] [Abstract][Full Text] [Related]
15. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir. Bedel AN; Hemmelgarn TS; Kohli R Liver Transpl; 2012 Mar; 18(3):347-54. PubMed ID: 22139888 [TBL] [Abstract][Full Text] [Related]
16. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients. McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799 [TBL] [Abstract][Full Text] [Related]